Evacetrapib

	WikiDoc Resources for Evacetrapib
Articles
Most recent articles on Evacetrapib Most cited articles on Evacetrapib Review articles on Evacetrapib Articles on Evacetrapib in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Evacetrapib Images of Evacetrapib Photos of Evacetrapib Podcasts & MP3s on Evacetrapib Videos on Evacetrapib
Evidence Based Medicine
Cochrane Collaboration on Evacetrapib Bandolier on Evacetrapib TRIP on Evacetrapib
Clinical Trials
Ongoing Trials on Evacetrapib at Clinical Trials.gov Trial results on Evacetrapib Clinical Trials on Evacetrapib at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Evacetrapib NICE Guidance on Evacetrapib NHS PRODIGY Guidance FDA on Evacetrapib CDC on Evacetrapib
Books
Books on Evacetrapib
News
Evacetrapib in the news Be alerted to news on Evacetrapib News trends on Evacetrapib
Commentary
Blogs on Evacetrapib
Definitions
Definitions of Evacetrapib
Patient Resources / Community
Patient resources on Evacetrapib Discussion groups on Evacetrapib Patient Handouts on Evacetrapib Directions to Hospitals Treating Evacetrapib Risk calculators and risk factors for Evacetrapib
Healthcare Provider Resources
Symptoms of Evacetrapib Causes & Risk Factors for Evacetrapib Diagnostic studies for Evacetrapib Treatment of Evacetrapib
Continuing Medical Education (CME)
CME Programs on Evacetrapib
International
Evacetrapib en Espanol Evacetrapib en Francais
Business
Evacetrapib in the Marketplace Patents on Evacetrapib
Experimental / Informatics
List of terms related to Evacetrapib

Evacetrapib
	Error creating thumbnail: File missing
Names
	IUPAC name Trans-4-({(5S)-5-[{[3,5-bis(trifluoromethyl)phenyl]methyl}(2-methyl-2H-tetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzazepin-1-yl}methyl) cyclohexanecarboxylic acid
	Other names LY2484595
Identifiers
CAS Number	1186486-62-3 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2017179;
ChemSpider	26286916 ;
ECHA InfoCard	Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
KEGG	D10121 ;
	InChI InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20-,22-,26-/m0/s1 Key: IHIUGIVXARLYHP-YBXDKENTSA-N ; InChI=1/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20-,22-,26-/m0/s1 Key: IHIUGIVXARLYHP-YBXDKENTBY;
	SMILES O=C([C@H]1CC[C@H](CN2CCC[C@H](N(CC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C4=NN(C)N=N4)C5=CC(C)=CC(C)=C52)CC1)O;
Properties
Chemical formula	C31H36F6N6O2
Molar mass	638.66 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Template:Chembox E number

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Evacetrapib is a drug under development by Eli Lilly & Company (investigational name LY2484595) that inhibits cholesterylester transfer protein, which transfers and thereby increases high-density lipoprotein and lowers low-density lipoprotein. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease.^[1] The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure,^[2] which led to excess cardiac events when it was studied.^[2] Evacetrapib does not have the same effect.^[1] When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile.^[3]

Evacetrapib is one of two CETP inhibitors currently being evaluated (the other being anacetrapib).^[1] Two other CETP inhibitors (torcetrapib and dalcetrapib) were discontinued during trials due to increased deaths and little identifiable cardiovascular benefit (despite substantial increases in HDL). Some hypothesize that CETP inhibitors may still be useful in the treatment of dyslipidemia, though significant caution is warranted.^[2]

References

↑ ^1.0 ^1.1 ^1.2 Cao G, Beyer TP, Zhang Y; et al. (2011). "Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure". J. Lipid Res. 52 (12): 2169–76. doi:10.1194/jlr.M018069. PMID 21957197. Unknown parameter |month= ignored (help)
↑ ^2.0 ^2.1 ^2.2 Joy T, Hegele RA (2009). "The end of the road for CETP inhibitors after torcetrapib?". Curr. Opin. Cardiol. 24 (4): 364–71. doi:10.1097/HCO.0b013e32832ac166. PMID 19522058. Unknown parameter |month= ignored (help)
↑ Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE (2011). "Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol". JAMA. 306 (19): 2099–109. doi:10.1001/jama.2011.1649.

Template:Lipid modifying agents

[pmid21957197-1] 1.0 ^1.1 ^1.2 Cao G, Beyer TP, Zhang Y; et al. (2011). "Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure". J. Lipid Res. 52 (12): 2169–76. doi:10.1194/jlr.M018069. PMID 21957197. Unknown parameter |month= ignored (help)

[pmid19522058-2] 2.0 ^2.1 ^2.2 Joy T, Hegele RA (2009). "The end of the road for CETP inhibitors after torcetrapib?". Curr. Opin. Cardiol. 24 (4): 364–71. doi:10.1097/HCO.0b013e32832ac166. PMID 19522058. Unknown parameter |month= ignored (help)

[Nicholls-3] Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE (2011). "Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol". JAMA. 306 (19): 2099–109. doi:10.1001/jama.2011.1649.

[1]

[2]

[3]

Evacetrapib

Overview

References

Navigation menu